Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Regan JA, Cao Y, Dispenza MC, Ma S, Gordon LI, Petrich AM, Bochner BS. Regan JA, et al. Among authors: gordon li. J Allergy Clin Immunol. 2017 Sep;140(3):875-879.e1. doi: 10.1016/j.jaci.2017.03.013. Epub 2017 Apr 4. J Allergy Clin Immunol. 2017. PMID: 28389390 Free PMC article. No abstract available.
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN. Gentzler RD, et al. Among authors: gordon li. Br J Haematol. 2014 Jun;165(6):793-800. doi: 10.1111/bjh.12824. Epub 2014 Mar 15. Br J Haematol. 2014. PMID: 24628515 Free article.
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Gandhi MD, et al. Among authors: gordon li. Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878. Blood. 2014. PMID: 24786458 Free PMC article. No abstract available.
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. Galanina N, et al. Among authors: gordon li. Br J Haematol. 2018 Apr;181(2):264-267. doi: 10.1111/bjh.14544. Epub 2017 Apr 17. Br J Haematol. 2018. PMID: 28419407 Free PMC article. Clinical Trial. No abstract available.
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. Pearse WB, et al. Among authors: gordon li. Leuk Lymphoma. 2021 Dec;62(14):3493-3500. doi: 10.1080/10428194.2021.1957867. Epub 2021 Aug 2. Leuk Lymphoma. 2021. PMID: 34338127 Clinical Trial.
445 results